nach oben

Neurological Sciences

Erschienen in:

01.02.2019 | Original Article

Association of olfaction dysfunction with brain microstructure in prodromal Parkinson disease

verfasst von: Hossein Sanjari Moghaddam, Mahsa Dolatshahi, Elaheh Salardini, Mohammad Hadi Aarabi

Erschienen in: Neurological Sciences | Ausgabe 2/2019

Einloggen, um Zugang zu erhalten

Abstract

Objective

Although olfaction dysfunction is now considered as an established clinical marker of prodromal Parkinson disease (PD), little is known about the neural underpinnings of olfaction dysfunction in the prodromal phase of PD. The aim of this study was to examine the microstructural association of olfaction in prodromal PD compared to early stage drug-naïve PD patients.

Methods

Diffusion MRI connectometry was conducted on 18 early PD and 17 prodromal PD patients to investigate the differences in group in terms of altered connectivity, i.e., integrity of white matter tracts, and subsequently to study the correlation of University of Pennsylvania Smell Identification Test (UPSIT) score to white matter integrity in each group using a multiple regression model considering age, sex, RBD, and MoCA, as covariates.

Results

Individuals with prodromal PD had significantly higher quantitative anisotropy (QA) comparing with PD patients in bilateral middle cerebellar peduncles and right arcuate fasciculus. Multiple regression analysis in prodromal PD demonstrated positive association between UPSIT score and connectivity in left and right subgenual cingulum, right inferior fronto-occipital fasciculus, left corticospinal tract, left parietopontine, left corticothalamic tract, and the body and the splenium of corpus callosum.

Conclusion

These results indicate that PD and prodromal PD patients, which were matched for sex, UPSIT, and MoCA scores, have different white matter fiber architecture. Thus, it is postulated that olfaction dysfunction in prodromal and early clinical phases of PD may involve distinct pathogenesis. Increased network connectivity in prodromal and early PD may suggest the neural compensation.

Brooks DJ (1998) The early diagnosis of Parkinson’s disease. Ann Neurol 44(3 Suppl 1):S10–S18PubMedCrossRef

Ghazi Sherbaf F, Rostam Abadi Y, Mojtahed Zadeh M, Ashraf-Ganjouei A, Sanjari Moghaddam H, Aarabi MH (2018) Microstructural changes in patients with Parkinson’s disease comorbid with REM sleep behaviour disorder and depressive symptoms. Front Neurol 9:441. https://doi.org/10.3389/fneur.2018.00441 PubMedPubMedCentralCrossRef

Ansari M, Adib Moradi S, Ghazi Sherbaf F, Hedayatnia A, Aarabi MH (2018) Comparison of structural connectivity in Parkinson’s disease with depressive symptoms versus non-depressed: a diffusion MRI connectometry study. Int Psychogeriatr:1–8. https://doi.org/10.1017/s1041610218000170

Ashraf-Ganjouei A, Majd A, Javinani A, Aarabi MH (2018) Autonomic dysfunction and white matter microstructural changes in drug-naïve patients with Parkinson’s disease. PeerJ 6:e5539. https://doi.org/10.7717/peerj.5539 PubMedPubMedCentralCrossRef

Berg D, Postuma RB, Adler CH, Bloem BR, Chan P, Dubois B, Gasser T, Goetz CG, Halliday G, Joseph L, Lang AE, Liepelt-Scarfone I, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2015) MDS research criteria for prodromal Parkinson’s disease. Mov Dis 30(12):1600–1611. https://doi.org/10.1002/mds.26431 CrossRef

Berg D, Postuma RB, Bloem B, Chan P, Dubois B, Gasser T, Goetz CG, Halliday GM, Hardy J, Lang AE, Litvan I, Marek K, Obeso J, Oertel W, Olanow CW, Poewe W, Stern M, Deuschl G (2014) Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson’s disease. Mov Dis 29(4):454–462. https://doi.org/10.1002/mds.25844 CrossRef

Salat D, Noyce AJ, Schrag A, Tolosa E (2016) Challenges of modifying disease progression in prediagnostic Parkinson’s disease. Lancet Neurol 15(6):637–648. https://doi.org/10.1016/S1474-4422(16)00060-0 PubMedCrossRef

Postuma RB, Aarsland D, Barone P, Burn DJ, Hawkes CH, Oertel W, Ziemssen T (2012) Identifying prodromal Parkinson’s disease: pre-motor disorders in Parkinson’s disease. Mov Disord 27(5):617–626PubMedCrossRef

Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 24(2):197–211CrossRefPubMed

10.

Chu S, Downes JJ (2000) Odour-evoked autobiographical memories: psychological investigations of Proustian phenomena. Chem Senses 25(1):111–116PubMedCrossRef

11.

Doty RL (2012) Olfactory dysfunction in Parkinson disease. Nat Rev Neurol 8(6):329–339. https://doi.org/10.1038/nrneurol.2012.80 PubMedCrossRef

12.

Berg D, Marek K, Ross GW, Poewe W (2012) Defining at-risk populations for Parkinson’s disease: lessons from ongoing studies. Mov Disord 27(5):656–665PubMedCrossRef

13.

Haehner A, Hummel T, Hummel C, Sommer U, Junghanns S, Reichmann H (2007) Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 22(6):839–842PubMedCrossRef

14.

Ross GW, Petrovitch H, Abbott RD, Tanner CM, Popper J, Masaki K, Launer L, White LR (2008) Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 63(2):167–173PubMedCrossRef

15.

Ponsen MM, Stoffers D, Twisk JW, Wolters EC, Berendse HW (2009) Hyposmia and executive dysfunction as predictors of future Parkinson’s disease: a prospective study. Mov Disord 24(7):1060–1065PubMedCrossRef

16.

Postuma RB, Gagnon JF, Vendette M, Desjardins C, Montplaisir JY (2011) Olfaction and color vision identify impending neurodegeneration in rapid eye movement sleep behavior disorder. Ann Neurol 69(5):811–818PubMedCrossRef

17.

Mahlknecht P, Iranzo A, Högl B, Frauscher B, Müller C, Santamaría J, Tolosa E, Serradell M, Mitterling T, Gschliesser V (2015) Olfactory dysfunction predicts early transition to a Lewy body disease in idiopathic RBD. Neurology 84(7):654–658PubMedCrossRef

18.

Jennings D, Stern M, Siderowf A, Eberly S, Oakes D, Marek K (2015) Longitudinal imaging and phenoconversion in the PARS prodromal cohort. Mov Disord 30:S383

19.

Postuma RB, Berg D (2016) Advances in markers of prodromal Parkinson disease. Nat Rev Neurol 12(11):622–634PubMedCrossRef

20.

Rodríguez-violante M, Ospina-García N, Pérez-Lohman C, Cervantes-Arriaga A (2017) Spotlight on olfactory dysfunction in Parkinson’s disease. J Parkinsonism Restless Legs Syndr 55:33–41. https://doi.org/10.2147/JPRLS.S125390

21.

Haehner A, Boesveldt S, Berendse HW, Mackay-Sim A, Fleischmann J, Silburn PA, Johnston AN, Mellick GD, Herting B, Reichmann H, Hummel T (2009) Prevalence of smell loss in Parkinson’s disease--a multicenter study. Parkinsonism Relat Disord 15(7):490–494. https://doi.org/10.1016/j.parkreldis.2008.12.005 PubMedCrossRef

22.

Ponsen MM, Stoffers D, Booij J, van Eck-Smit BL, Wolters E, Berendse HW (2004) Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 56(2):173–181. https://doi.org/10.1002/ana.20160 PubMedCrossRef

23.

Stern MB, Doty RL, Dotti M, Corcoran P, Crawford D, McKeown DA, Adler C, Gollomp S, Hurtig H (1994) Olfactory function in Parkinson’s disease subtypes. Neurology 44(2):266–268PubMedCrossRef

24.

Doty RL, Shaman P, Dann M (1984) Development of the University of Pennsylvania Smell Identification Test: a standardized microencapsulated test of olfactory function. Physiol Behav 32(3):489–502PubMedCrossRef

25.

Baba T, Kikuchi A, Hirayama K, Nishio Y, Hosokai Y, Kanno S, Hasegawa T, Sugeno N, Konno M, Suzuki K, Takahashi S, Fukuda H, Aoki M, Itoyama Y, Mori E, Takeda A (2012) Severe olfactory dysfunction is a prodromal symptom of dementia associated with Parkinson’s disease: a 3 year longitudinal study. Brain 135(Pt 1):161–169. https://doi.org/10.1093/brain/awr321 PubMedCrossRef

26.

Baba T, Takeda A, Kikuchi A, Nishio Y, Hosokai Y, Hirayama K, Hasegawa T, Sugeno N, Suzuki K, Mori E, Takahashi S, Fukuda H, Itoyama Y (2011) Association of olfactory dysfunction and brain. Metabolism in Parkinson’s disease. Mov Dis 26(4):621–628. https://doi.org/10.1002/mds.23602 CrossRef

27.

Berendse HW, Booij J, Francot CM, Bergmans PL, Hijman R, Stoof JC, Wolters EC (2001) Subclinical dopaminergic dysfunction in asymptomatic Parkinson’s disease patients’ relatives with a decreased sense of smell. Ann Neurol 50(1):34–41PubMedCrossRef

28.

Bohnen NI, Gedela S, Herath P, Constantine GM, Moore RY (2008) Selective hyposmia in Parkinson disease: association with hippocampal dopamine activity. Neurosci Lett 447(1):12–16. https://doi.org/10.1016/j.neulet.2008.09.070 PubMedPubMedCentralCrossRef

29.

Bohnen NI, Gedela S, Kuwabara H, Constantine GM, Mathis CA, Studenski SA, Moore RY (2007) Selective hyposmia and nigrostriatal dopaminergic denervation in Parkinson’s disease. J Neurol 254(1):84–90. https://doi.org/10.1007/s00415-006-0284-y PubMedCrossRef

30.

Bohnen NI, Muller ML, Kotagal V, Koeppe RA, Kilbourn MA, Albin RL, Frey KA (2010) Olfactory dysfunction, central cholinergic integrity and cognitive impairment in Parkinson’s disease. Brain 133(Pt 6):1747–1754. https://doi.org/10.1093/brain/awq079 PubMedPubMedCentralCrossRef

31.

Siderowf A, Newberg A, Chou KL, Lloyd M, Colcher A, Hurtig HI, Stern MB, Doty RL, Mozley PD, Wintering N, Duda JE, Weintraub D, Moberg PJ (2005) [99mTc]TRODAT-1 SPECT imaging correlates with odor identification in early Parkinson disease. Neurology 64(10):1716–1720. https://doi.org/10.1212/01.wnl.0000161874.52302.5d PubMedCrossRef

32.

Su M, Wang S, Fang W, Zhu Y, Li R, Sheng K, Zou D, Han Y, Wang X, Cheng O (2015) Alterations in the limbic/paralimbic cortices of Parkinson’s disease patients with hyposmia under resting-state functional MRI by regional homogeneity and functional connectivity analysis. Parkinsonism Relat Disord 21(7):698–703. https://doi.org/10.1016/j.parkreldis.2015.04.006 PubMedCrossRef

33.

Yeh F-C, Tang P-F, Tseng W-YI (2013) Diffusion MRI connectometry automatically reveals affected fiber pathways in individuals with chronic stroke. NeuroImage: Clinical 2:912–921. https://doi.org/10.1016/j.nicl.2013.06.014 CrossRef

34.

Leemans A, Jeurissen B, Sijbers J, Jones D (2009) ExploreDTI: a graphical toolbox for processing, analyzing, and visualizing diffusion MR data. In: 17th Annual Meeting of Intl Soc Mag Reson Med. p 3537

35.

Ghazi Sherbaf F, Mojtahed Zadeh M, Haghshomar M, Aarabi MH (2018) Posterior limb of the internal capsule predicts poor quality of life in patients with Parkinson’s disease: connectometry approach. Acta Neurol Belg. https://doi.org/10.1007/s13760-018-0910-3

36.

Ghazi Sherbaf F, Same K, Aarabi MH (2018) High angular resolution diffusion imaging correlates of depression in Parkinson’s disease: a connectometry study. Acta Neurol Belg. https://doi.org/10.1007/s13760-018-0937-5

37.

Mojtahed Zadeh M, Ashraf-Ganjouei A, Ghazi Sherbaf F, Haghshomar M, Aarabi MH (2018) White matter tract alterations in drug-naive Parkinson’s disease patients with impulse control disorders. Front Neurol 9:163. https://doi.org/10.3389/fneur.2018.00163 PubMedPubMedCentralCrossRef

38.

Lee EY, Eslinger PJ, Du G, Kong L, Lewis MM, Huang X (2014) Olfactory-related cortical atrophy is associated with olfactory dysfunction in Parkinson’s disease. Mov Dis 29(9):1205–1208. https://doi.org/10.1002/mds.25829 CrossRef

39.

van Uem JM, Marinus J, Canning C, van Lummel R, Dodel R, Liepelt-Scarfone I, Berg D, Morris ME, Maetzler W (2016) Health-related quality of life in patients with Parkinson’s disease—a systematic review based on the ICF model. Neurosci Biobehav Rev 61:26–34PubMedCrossRef

40.

Wattendorf E, Welge-Lussen A, Fiedler K, Bilecen D, Wolfensberger M, Fuhr P, Hummel T, Westermann B (2009) Olfactory impairment predicts brain atrophy in Parkinson’s disease. J Neurosci 29(49):15410–15413. https://doi.org/10.1523/jneurosci.1909-09.2009 PubMedCrossRefPubMedCentral

41.

Kwon HG, Hong JH, Jang SH (2011) Anatomic location and somatotopic arrangement of the corticospinal tract at the cerebral peduncle in the human brain. AJNR Am J Neuroradiol 32(11):2116–2119. https://doi.org/10.3174/ajnr.A2660 PubMedCrossRefPubMedCentral

42.

Marek K, Jennings D, Lasch S, Siderowf A, Tanner C, Simuni T, Coffey C, Kieburtz K, Flagg E, Chowdhury S (2011) The parkinson progression marker initiative (PPMI). Prog Neurobiol 95(4):629–635CrossRefPubMedCentral

43.

Yeh FC, Tseng WY (2011) NTU-90: a high angular resolution brain atlas constructed by q-space diffeomorphic reconstruction. NeuroImage 58(1):91–99. https://doi.org/10.1016/j.neuroimage.2011.06.021 PubMedCrossRef

44.

Yeh F-C, Verstynen TD, Wang Y, Fernández-Miranda JC, Tseng W-YI (2013) Deterministic diffusion fiber tracking improved by quantitative anisotropy. PLoS One 8(11):e80713. https://doi.org/10.1371/journal.pone.0080713 PubMedPubMedCentralCrossRef

45.

Schmahmann JD, Smith EE, Eichler FS, Filley CM (2008) Cerebral white matter: neuroanatomy, clinical neurology, and neurobehavioral correlates. Ann N Y Acad Sci 1142:266–309. https://doi.org/10.1196/annals.1444.017 PubMedPubMedCentralCrossRef

46.

Tessa C, Lucetti C, Giannelli M, Diciotti S, Poletti M, Danti S, Baldacci F, Vignali C, Bonuccelli U, Mascalchi M, Toschi N (2014) Progression of brain atrophy in the early stages of Parkinson’s disease: a longitudinal tensor-based morphometry study in de novo patients without cognitive impairment. Hum Brain Mapp 35(8):3932–3944. https://doi.org/10.1002/hbm.22449 PubMedCrossRefPubMedCentral

47.

Ansari M, Rahmani F, Dolatshahi M, Pooyan A, Aarabi MH (2017) Brain pathway differences between Parkinson’s disease patients with and without REM sleep behavior disorder. Sleep Breath 21(1):155–161. https://doi.org/10.1007/s11325-016-1435-8 PubMedCrossRef

48.

Hall JM, Ehgoetz Martens KA, Walton CC, O'Callaghan C, Keller PE, Lewis SJ, Moustafa AA (2016) Diffusion alterations associated with Parkinson’s disease symptomatology: a review of the literature. Parkinsonism Relat Disord 33:12–26. https://doi.org/10.1016/j.parkreldis.2016.09.026 PubMedCrossRef

49.

Sobhani S, Rahmani F, Aarabi MH, Sadr AV (2017) Exploring white matter microstructure and olfaction dysfunction in early parkinson disease: diffusion MRI reveals new insight. Brain Imaging Behav. https://doi.org/10.1007/s11682-017-9781-0

50.

Wen MC, Heng HSE, Hsu JL, Xu Z, Liew GM, Au WL, Chan LL, Tan LCS, Tan EK (2017) Structural connectome alterations in prodromal and de novo Parkinson’s disease patients. Parkinsonism Relat Disord 45:21–27. https://doi.org/10.1016/j.parkreldis.2017.09.019 PubMedCrossRef

51.

Nigro S, Riccelli R, Passamonti L, Arabia G, Morelli M, Nistico R, Novellino F, Salsone M, Barbagallo G, Quattrone A (2016) Characterizing structural neural networks in de novo Parkinson disease patients using diffusion tensor imaging. Hum Brain Mapp 37(12):4500–4510. https://doi.org/10.1002/hbm.23324 PubMedCrossRefPubMedCentral

52.

Wei L, Zhang J, Long Z, Wu GR, Hu X, Zhang Y, Wang J (2014) Reduced topological efficiency in cortical-basal Ganglia motor network of Parkinson’s disease: a resting state fMRI study. PLoS One 9(10):e108124. https://doi.org/10.1371/journal.pone.0108124 PubMedPubMedCentralCrossRef

53.

Scherfler C, Frauscher B, Schocke M, Iranzo A, Gschliesser V, Seppi K, Santamaria J, Tolosa E, Hogl B, Poewe W (2011) White and gray matter abnormalities in idiopathic rapid eye movement sleep behavior disorder: a diffusion-tensor imaging and voxel-based morphometry study. Ann Neurol 69(2):400–407. https://doi.org/10.1002/ana.22245 PubMedCrossRef

54.

Shao Y, Wang L, Ye E, Jin X, Ni W, Yang Y, Wen B, Hu D, Yang Z (2013) Decreased thalamocortical functional connectivity after 36 hours of total sleep deprivation: evidence from resting state FMRI. PLoS One 8(10):e78830. https://doi.org/10.1371/journal.pone.0078830 PubMedPubMedCentralCrossRef

55.

Welge-Lussen A, Wattendorf E, Schwerdtfeger U, Fuhr P, Bilecen D, Hummel T, Westermann B (2009) Olfactory-induced brain activity in Parkinson’s disease relates to the expression of event-related potentials: a functional magnetic resonance imaging study. Neuroscience 162(2):537–543. https://doi.org/10.1016/j.neuroscience.2009.04.050 PubMedCrossRef

56.

Gottfried JA, Zald DH (2005) On the scent of human olfactory orbitofrontal cortex: meta-analysis and comparison to non-human primates. Brain Res Brain Res Rev 50(2):287–304. https://doi.org/10.1016/j.brainresrev.2005.08.004 PubMedCrossRef

57.

Ibarretxe-Bilbao N, Junque C, Marti MJ, Valldeoriola F, Vendrell P, Bargallo N, Zarei M, Tolosa E (2010) Olfactory impairment in Parkinson’s disease and white matter abnormalities in central olfactory areas: a voxel-based diffusion tensor imaging study. Mov Dis 25(12):1888–1894. https://doi.org/10.1002/mds.23208 CrossRef

58.

Wen M-C, Xu Z, Lu Z, Chan LL, Tan EK, Tan LCS (2017) Microstructural network alterations of olfactory dysfunction in newly diagnosed Parkinson’s disease. Sci Rep 7(1):12559. https://doi.org/10.1038/s41598-017-12947-7 PubMedPubMedCentralCrossRef

59.

Sunwoo MK, Cha J, Ham JH, Song SK, Hong JY, Lee JM, Sohn YH, Lee PH (2015) Olfactory performance and resting state functional connectivity in non-demented drug naive patients with Parkinson’s disease. Hum Brain Mapp 36(5):1716–1727. https://doi.org/10.1002/hbm.22732 PubMedCrossRef

Titel: Association of olfaction dysfunction with brain microstructure in prodromal Parkinson disease
verfasst von: Hossein Sanjari Moghaddam
Mahsa Dolatshahi
Elaheh Salardini
Mohammad Hadi Aarabi
Publikationsdatum: 01.02.2019
Verlag: Springer International Publishing
Erschienen in: Neurological Sciences / Ausgabe 2/2019
Print ISSN: 1590-1874
Elektronische ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-018-3629-2

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Objective

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2019

Was the subject portrayed in “A Man” by Cornelis Anthonisz around 1530 really affected by progressive supranuclear palsy?

Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease

A case of primary angiitis of the central nervous system presenting with diffuse cerebral microbleeds and recurrent intracranial hemorrhage

MR evaluation of encephalic leukoaraiosis in sudden sensorineural hearing loss (SSNHL) patients

Decreasing 123I-ioflupane SPECT accumulation and 123I-MIBG myocardial scintigraphy uptake in a patient with a novel homozygous mutation in the ZFYVE26 gene